A global biopharma focused on severe diseases with operations in more than 40 countries and global revenue of €3.6 billion in 2007
A leader in allergy and epilepsy with 12 large and small molecules in the pipeline, spanning 16 diseases, from Crohn’s and Parkinson’s to multiple sclerosis.
A leader in antibody research supported by proprietary chemistry and over 30 major R&D partners.
